A citation-based method for searching scientific literature

Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
Times Cited: 25







List of co-cited articles
165 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
73
40

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
76
40

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Richard B Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg. Dermatol Ther (Heidelb) 2020
21
42

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
80
32


Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
128
28

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, Lesley S Exton, M Firouz Mohd Mustapa, Eleanor Samarasekera, A David Burden, Ruth Murphy, Caroline M Owen, Richard Parslew,[...]. J Invest Dermatol 2017
89
28

Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
20
35


Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
L M Sawyer, L Cornic, L Å Levin, C Gibbons, A H Møller, G B Jemec. J Eur Acad Dermatol Venereol 2019
55
28

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
278
28

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Najeeda Yasmeen, Laura M Sawyer, Kinga Malottki, Lars-Åke Levin, Eydna Didriksen Apol, Gregor B Jemec. J Dermatolog Treat 2022
17
41

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
495
28

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
28

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
150
24


Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
803
24



Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Anne M Loos, Shanshan Liu, Celia Segel, Daniel A Ollendorf, Steven D Pearson, Jeffrey A Linder. J Am Acad Dermatol 2018
34
20


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons, Anders Holmen Møller. J Dermatolog Treat 2018
24
20


Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
473
20

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
360
20

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
288
20

Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Yayoi Tada, Rei Watanabe, Hisashi Noma, Yasumasa Kanai, Takanobu Nomura, Kenji Kaneko. J Dermatol Sci 2020
13
38

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
54
20

Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada.
Aditya K Gupta, Deanne Daigle, Danika C A Lyons. J Cutan Med Surg 2014
11
36

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Alan Menter, Steven R Feldman, Gerald D Weinstein, Kim Papp, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Cynthia Arnold, Alice B Gottlieb. J Am Acad Dermatol 2007
350
16

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
295
16

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.
Wenjun Geng, Jianhua Zhao, Jixing Fu, Huamin Zhang, Shaohua Qiao. Exp Ther Med 2018
13
30


Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis.
Andrea Messori, Sabrina Trippoli, Valeria Fadda, Dario Maratea, Claudio Marinai. Drugs Real World Outcomes 2015
7
57

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
108
16

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, Craig L Leonardi, Yves Poulin, Janice Drew, Luke Peterson, Catherine Arendt, Daniel Burge, Kristian Reich. J Am Acad Dermatol 2018
91
16

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
116
16

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
S K Mahil, M C Ezejimofor, L S Exton, L Manounah, A D Burden, L C Coates, M de Brito, A McGuire, R Murphy, C M Owen,[...]. Br J Dermatol 2020
23
17

Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Weiguang Xue, Paranjoy Saharia, Emma Gray, Shoghag Khoudigian-Sinani, Véronique Gaudet, Martin Barbeau, Kim Papp. J Cutan Med Surg 2020
5
80

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.
Rosa Parisi, Ireny Y K Iskandar, Evangelos Kontopantelis, Matthias Augustin, Christopher E M Griffiths, Darren M Ashcroft. BMJ 2020
165
16

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
A Blauvelt, C Leonardi, B Elewski, J J Crowley, L C Guenther, M Gooderham, R G Langley, R Vender, A Pinter, C E M Griffiths,[...]. Br J Dermatol 2021
21
19

Update on psoriasis immunopathogenesis and targeted immunotherapy.
Satveer K Mahil, Francesca Capon, Jonathan N Barker. Semin Immunopathol 2016
119
12

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
289
12



Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis.
Chris Cameron, Brian Hutton, Cheryl Druchok, Sean McElligott, Sandhya Nair, Agata Schubert, Aaron Situ, Abhishek Varu, Reggie Villacorta. J Comp Eff Res 2018
18
16


Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Kristian Reich, Rodney Sinclair, Graeme Roberts, Christopher E M Griffiths, Maggie Tabberer, Jonathan Barker. Curr Med Res Opin 2008
37
12

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta Węgłowska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson,[...]. J Am Acad Dermatol 2018
73
12

Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.
April W Armstrong, Steven R Feldman, Neil J Korman, Xiangyi Meng, Adriana Guana, Judit Nyirady, Vivian Herrera, Yang Zhao. J Dermatolog Treat 2017
12
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.